Glaxo reaches $150 mln settlement in nasal spray litigation | BioSpace - Financial Content

BioSpace.com

Biotech and Pharmaceutical
News & Jobs

NEWSLETTERS
FREENewsletters
Archive

NEWS
News bySubject
News byDisease
News byDate
PLoS
SearchNews

CAREER NETWORK
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

DIVERSITY

HOTBEDS
Regional News
BiotechBay™
BiotechBeach™
Genetown™
PharmCountry™
BioCapital™
BioMidwest™
BioNC™
BioForest™
SouthernPharm™
BioCanadaEast™
US Device™

INVESTOR
Market Summary
News
IPOs

PROFILES
CompanyProfiles

START UPS
Companies
Events

INTELLIGENCE
BioPharm Insight

INDUSTRY EVENTS
Biotech Events
Post an Event

RESOURCES
RealEstate
Business Opportunities


Markets Stocks Mutual Funds & ETF's Sectors Tools Overview Market News Market Videos Currencies International Treasury & Bonds Search InvestCenter Recent Quotes View Full List My Watchlist Create Watchlist Indicators Dow Jones Industrial Average NASDAQ Composite Standard & Poors 500 NYSE COMPOSITE INDX Gold Crude Oil Glaxo reaches $150 mln settlement in nasal spray litigation By: Reuters: Company News Posted on December 19, 2012 at 12:11 PM EST Dec 19 (Reuters) - British drugmaker GlaxoSmithKline Plc has reached a $150 million preliminary settlement with U.S. drug wholesalers who claimed the company improperly delayed entry to the market of generic alternatives to its nasal spray Flonase, according to court documents. Read More >> Related Stocks: AmerisourceBergen Corp. Cardinal Health, Inc. GlaxoSmithKline PLC ADS McKesson Corp. Stock Market XML and JSON Data API provided by FinancialContent Services, Inc. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes. Markets are closed on certain holidays. Stock Market Holiday List By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. Press Release Service provided by PRConnect. Stock quotes supplied by Telekurs USA Postage Rates Bots go here